Hypomethylating agents for urologic cancers

Ajjai S. Alva, Noah M. Hahn, Ana M. Aparicio, Rakesh Singal, Sarvari Yellapragada, Guru Sonpavde

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Silencing of tumor suppressor genes by promoter-region methylation as an epigenetic mechanism of gene regulation is increasingly recognized as beneficial in cancer. Initially developed as cytotoxic high-dose therapies, azacitidine and decitabine are now being reinvestigated in lower-dose cancer treatment regimens with a different paradigm - hypomethylation. Recent evidence for benefit in myelodysplastic syndromes and acute myeloid leukemias has renewed interest in hypomethylation as a therapeutic option in epithelial cancers. In this article, we describe the mechanistic aspects of DNA methylation, which alters gene expression, and review the evidence for hypomethylation as a therapeutic option in urologic cancers. Potential correlative studies that may assist in developing tailored therapy with hypomethylating agents are reviewed. Given that the population with urologic cancers is typically elderly with multiple comorbidities, the excellent tolerability of lower-dose hypomethylating agents provides a high therapeutic index and rational development is warranted, bearing in mind that the cytostatic and delayed activity present challenges in the choice of appropriate trial end points.

Original languageEnglish
Pages (from-to)447-463
Number of pages17
JournalFuture Oncology
Volume7
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Urologic Neoplasms
decitabine
Therapeutics
Azacitidine
Neoplasms
Myelodysplastic Syndromes
Cytostatic Agents
DNA Methylation
Tumor Suppressor Genes
Genetic Promoter Regions
Acute Myeloid Leukemia
Epigenomics
Methylation
Comorbidity
Gene Expression
Population
Genes

Keywords

  • hypomethylating agents
  • prostate cancer
  • renal cell carcinoma
  • urologic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Alva, A. S., Hahn, N. M., Aparicio, A. M., Singal, R., Yellapragada, S., & Sonpavde, G. (2011). Hypomethylating agents for urologic cancers. Future Oncology, 7(3), 447-463. https://doi.org/10.2217/fon.11.9

Hypomethylating agents for urologic cancers. / Alva, Ajjai S.; Hahn, Noah M.; Aparicio, Ana M.; Singal, Rakesh; Yellapragada, Sarvari; Sonpavde, Guru.

In: Future Oncology, Vol. 7, No. 3, 01.03.2011, p. 447-463.

Research output: Contribution to journalArticle

Alva, AS, Hahn, NM, Aparicio, AM, Singal, R, Yellapragada, S & Sonpavde, G 2011, 'Hypomethylating agents for urologic cancers', Future Oncology, vol. 7, no. 3, pp. 447-463. https://doi.org/10.2217/fon.11.9
Alva AS, Hahn NM, Aparicio AM, Singal R, Yellapragada S, Sonpavde G. Hypomethylating agents for urologic cancers. Future Oncology. 2011 Mar 1;7(3):447-463. https://doi.org/10.2217/fon.11.9
Alva, Ajjai S. ; Hahn, Noah M. ; Aparicio, Ana M. ; Singal, Rakesh ; Yellapragada, Sarvari ; Sonpavde, Guru. / Hypomethylating agents for urologic cancers. In: Future Oncology. 2011 ; Vol. 7, No. 3. pp. 447-463.
@article{e4bf225dd89d4dac891be248775b54ed,
title = "Hypomethylating agents for urologic cancers",
abstract = "Silencing of tumor suppressor genes by promoter-region methylation as an epigenetic mechanism of gene regulation is increasingly recognized as beneficial in cancer. Initially developed as cytotoxic high-dose therapies, azacitidine and decitabine are now being reinvestigated in lower-dose cancer treatment regimens with a different paradigm - hypomethylation. Recent evidence for benefit in myelodysplastic syndromes and acute myeloid leukemias has renewed interest in hypomethylation as a therapeutic option in epithelial cancers. In this article, we describe the mechanistic aspects of DNA methylation, which alters gene expression, and review the evidence for hypomethylation as a therapeutic option in urologic cancers. Potential correlative studies that may assist in developing tailored therapy with hypomethylating agents are reviewed. Given that the population with urologic cancers is typically elderly with multiple comorbidities, the excellent tolerability of lower-dose hypomethylating agents provides a high therapeutic index and rational development is warranted, bearing in mind that the cytostatic and delayed activity present challenges in the choice of appropriate trial end points.",
keywords = "hypomethylating agents, prostate cancer, renal cell carcinoma, urologic cancer",
author = "Alva, {Ajjai S.} and Hahn, {Noah M.} and Aparicio, {Ana M.} and Rakesh Singal and Sarvari Yellapragada and Guru Sonpavde",
year = "2011",
month = "3",
day = "1",
doi = "10.2217/fon.11.9",
language = "English",
volume = "7",
pages = "447--463",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Hypomethylating agents for urologic cancers

AU - Alva, Ajjai S.

AU - Hahn, Noah M.

AU - Aparicio, Ana M.

AU - Singal, Rakesh

AU - Yellapragada, Sarvari

AU - Sonpavde, Guru

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Silencing of tumor suppressor genes by promoter-region methylation as an epigenetic mechanism of gene regulation is increasingly recognized as beneficial in cancer. Initially developed as cytotoxic high-dose therapies, azacitidine and decitabine are now being reinvestigated in lower-dose cancer treatment regimens with a different paradigm - hypomethylation. Recent evidence for benefit in myelodysplastic syndromes and acute myeloid leukemias has renewed interest in hypomethylation as a therapeutic option in epithelial cancers. In this article, we describe the mechanistic aspects of DNA methylation, which alters gene expression, and review the evidence for hypomethylation as a therapeutic option in urologic cancers. Potential correlative studies that may assist in developing tailored therapy with hypomethylating agents are reviewed. Given that the population with urologic cancers is typically elderly with multiple comorbidities, the excellent tolerability of lower-dose hypomethylating agents provides a high therapeutic index and rational development is warranted, bearing in mind that the cytostatic and delayed activity present challenges in the choice of appropriate trial end points.

AB - Silencing of tumor suppressor genes by promoter-region methylation as an epigenetic mechanism of gene regulation is increasingly recognized as beneficial in cancer. Initially developed as cytotoxic high-dose therapies, azacitidine and decitabine are now being reinvestigated in lower-dose cancer treatment regimens with a different paradigm - hypomethylation. Recent evidence for benefit in myelodysplastic syndromes and acute myeloid leukemias has renewed interest in hypomethylation as a therapeutic option in epithelial cancers. In this article, we describe the mechanistic aspects of DNA methylation, which alters gene expression, and review the evidence for hypomethylation as a therapeutic option in urologic cancers. Potential correlative studies that may assist in developing tailored therapy with hypomethylating agents are reviewed. Given that the population with urologic cancers is typically elderly with multiple comorbidities, the excellent tolerability of lower-dose hypomethylating agents provides a high therapeutic index and rational development is warranted, bearing in mind that the cytostatic and delayed activity present challenges in the choice of appropriate trial end points.

KW - hypomethylating agents

KW - prostate cancer

KW - renal cell carcinoma

KW - urologic cancer

UR - http://www.scopus.com/inward/record.url?scp=79953138219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953138219&partnerID=8YFLogxK

U2 - 10.2217/fon.11.9

DO - 10.2217/fon.11.9

M3 - Article

C2 - 21417907

AN - SCOPUS:79953138219

VL - 7

SP - 447

EP - 463

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -